RxDoctor Payments DataLook up a doctor →

Annette Abril, MD

Rheumatology · Kingsport, TNNPI 1013127430

Payments from drug & device makers

$43,642in general payments, 2019–2025

Across 922 payments — averaging $47.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$33K
  • Amgen$2K
  • Novartis$2K
  • Pfizer$1K
  • Johnson & Johnson$936
  • UCB, Inc.$930
  • plus $3K from 20 others
$6,819in research payments, 2019–2025

Across 5 payments — averaging $1363.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$7K

What the payments were for

  • Food & beverage$13,88098%
  • Education$2202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$43,642 in reported general payments places this provider in the 80th percentile of 127 rheumatology providers in Tennessee.

See all rheumatology providers in Tennessee

Medicare billing

Part B allowed, 2024
$1,282,538
Medicare patients
343
Services billed
84,646

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab72$602,234
Enbrel SureclickEtanercept55$456,582
RinvoqUpadacitinib35$259,729
Xeljanz XrTofacitinib Citrate28$202,324
Actemra ActpenTocilizumab23$103,743
Orencia ClickjectAbatacept15$96,507
OtezlaApremilast16$78,135
Hydroxychloroquine Sulfate450$18,039
MethotrexateMethotrexate Sodium462$12,063
Leflunomide65$4,323
Duloxetine Hcl151$3,555
Prednisone315$2,457
Colchicine23$2,325
Gabapentin268$1,813
Pilocarpine Hcl32$1,519

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$33,493$259,72935 claims
AmgenOtezla$2,059$78,13516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 127 rheumatology providers in Tennessee.

Other rheumatology in Kingsport

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →